ChemoCentryx Announces FDA Approval of TAVNEOS™ 

-- First FDA-approved orally-administered inhibitor of the complement 5a receptor --

Related Keywords

United States , Japan , Stephanie Tomei , Vifor Pharma , Chemocentryx , Susanm Kanaya , Hidradenitis Suppurativa , Petera Merkel , Lee Roth , Joyce Kullman , Thomasj Schall , Vasculitis Foundation , European Commission , Burns Mcclellan Inc , Drug Administration , Perelman School Of Medicine , Nasdaq , Exchange Commission , Chemocentryx Kidney Health Alliance , European Medicines Agency , University Of Pennsylvania , Vasculitis Clinical Research Consortium , Chemocentryx Inc , Chief Executive Officer , Perelman School , Executive Director , New England Journal , Birmingham Vasculitis Activity Score , Kidney Health Alliance , Webcast Chemocentryx , Prescribing Information , Hypersensitivity Reactions , Full Prescribing Information , Medication Guide , Lupus Nephritis , Associated Vasculitis , Looking Statements Chemocentryx , Annual Report , Private Securities Litigation Reform Act , Executive Vice President , Chief Financial , Administrative Officer , Dburns Mcclellan , Money , Ational ,